Generic HIV/AIDS medications are less expensive but may also be less effective, says a new study from researchers at Massachusetts General Hospital. In an extensive trial, the researchers administered a generic replacement for the standard treatment Atripla.
It takes three generic drugs, tenofovir (Viread), emtricitabine (Emtriva) and efavirenz (Sustiva), to replace the medicine found in one Atripla pill. Each patient in the trial took all three medications and researchers found, on average, those taking the premium pill saved roughly 4.4 months of life.
The trade off, however, is that the generic drugs saved roughly $42,500 per patient:
"This is a trade-off that many of us will find emotionally difficult, and perhaps even ethically impossible, to recommend," said lead researcher Dr Rochelle Walensky.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.